2023 Pediatric Rheumatology Symposium

March 29-April 1, 2023. New Orleans, LA.

View by Number View by Title View Sessions

View by Date

Friday, March 31, 2023

5:00PM-6:00PM: Abstract Number: 110

Medications Affect Antibody Responses to COVID-19 Vaccinations in Children with Autoimmune Diseases

Posters: Clinical and Therapeutic II

5:00PM-6:00PM: Abstract Number: 111

Monitoring for Hypogammaglobulinemia After B-Cell Therapy in an Academic Pediatric Center

Posters: Clinical and Therapeutic II

5:00PM-6:00PM: Abstract Number: 128

Multisystem Inflammatory Syndrome in Children and Systemic Juvenile Idiopathic Arthritis Share Clinical Phenotypes and Genetic Contributions

Posters: Genetics and Pathogenesis II

5:00PM-6:00PM: Abstract Number: 134

Patient-Provider Communication in Pediatric Rheumatology

Posters: Quality, Health Services, and Education II

5:00PM-6:00PM: Abstract Number: 102

Preliminary Results from a Survey of Psychological Resilience Among JIA Patients

Posters: Clinical and Therapeutic II

5:00PM-6:00PM: Abstract Number: 104

Prevalence of Celiac Disease Among Children and Adolescents with Systemic Lupus Erythematosus (SLE)

Posters: Clinical and Therapeutic II

5:00PM-6:00PM: Abstract Number: 092

Procalcitonin Levels in Patients with Juvenile Dermatomyositis Compared to Healthy Controls

Posters: Clinical and Therapeutic II

5:00PM-6:00PM: Abstract Number: 113

Proportion of Patients with a Polyphasic Disease Course in Systemic-onset Juvenile Idiopathic Arthritis May Be Higher in the Age of Cytokine Inhibitors

Posters: Clinical and Therapeutic II

5:00PM-6:00PM: Abstract Number: 094

Provider Assessment of the Temporomandibular Joint in Juvenile Idiopathic Arthritis

Posters: Clinical and Therapeutic II

5:00PM-6:00PM: Abstract Number: 132

Quality Improvement Lessons in a New Practice

Posters: Quality, Health Services, and Education II

5:00PM-6:00PM: Abstract Number: 090

Safety Outcomes of Combined Biologics Use in Pediatric Rheumatology: A Single Center Experience

Posters: Clinical and Therapeutic II

5:00PM-6:00PM: Abstract Number: 118

Serum Hepatocyte Growth Factor in Children with Juvenile Idiopathic Arthritis

Posters: Clinical and Therapeutic II

5:00PM-6:00PM: Abstract Number: 097

Survey of Covid-19 Immunization and Infection in Patients with Systemic Juvenile Idiopathic Arthritis and Adult Onset Still’s Disease

Posters: Clinical and Therapeutic II

5:00PM-6:00PM: Abstract Number: 095

Systemic Juvenile Idiopathic Arthritis Associated Lung Disease in Europe

Posters: Clinical and Therapeutic II

5:00PM-6:00PM: Abstract Number: 120

The Brazilian Registry of Juvenile Dermatomyositis (JDM): I- Onset Clinical Features and Disease Activity Scores by DAS-20 over 2-Years-Follow Up

Posters: Clinical and Therapeutic II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].